Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Alabama at Birmingham
Non myeloablative transplant aims to achieve the immunological advantage of graft versus tumor effect as conventional myeloablative therapy without causing high treatment related toxicities. Non myeloablative transplant has been gaining wider acceptance as a way to achieve longer disease free and over all survival in patients with low grade B-cell malignancies, which otherwise is an incurable disease. Recent studies of non-myeloablative HSCT have demonstrated the powerful effect of graft versus leukemia alone against myeloma and other malignant B-cell malignancies if the transplant is performed for low grade, low volume disease.
Age
19–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage II or III non-progressive disease Multiple Myeloma.
CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.
≤ 70 years old.
Eligible and willing HLA matched related donor.
Bilirubin \<2xULN.
ALT and AST \<3xULN.
LVEF \> 40%.
Creatinine Clearance \>40mL/min.
Pulmonary function DLCO corrected to ≥ 70%.
Minimum performance score of 70%.
Platelet count \>130 x103 micro L.
LDH ≤1.5xULN.
No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.
No uncontrolled infections.
You may not be if
Age \>70 years old.
Performance status \<70%.
Uncontrolled infections or is HIV positive
Prior malignancies that are felt to have a \<80% probability of being cured.
Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.
Prior Allograft
History of rapidly growing disease at diagnosis or at any progression or have MDS.